This review summarizes the current understanding of the clinical significance of variable responses to antiplatelet therapy and the utility of ex vivo platelet function testing.
Answers are grounded in this paper and cite their sources.
Variable antiplatelet responses lack established clinical utility; leaves open whether ex vivo testing should guide therapy.
Ex vivo tests of platelet function show that platelet function and the response to antiplatelet therapy vary markedly from person to person. But just how clinically significant are ex vivo measurements of platelet function, and will changes we make based on such information translate into improved outcomes for patients? The authors summarize what is known and not known about the impact and clinical significance of variable response to antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Falluji et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: